NO330415B1 - Acylaminotiazol-derivater, fremgangsmate for fremstilling derav, anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer og farmasoytisk sammemsetning inneholdende de samme - Google Patents
Acylaminotiazol-derivater, fremgangsmate for fremstilling derav, anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer og farmasoytisk sammemsetning inneholdende de samme Download PDFInfo
- Publication number
- NO330415B1 NO330415B1 NO20053588A NO20053588A NO330415B1 NO 330415 B1 NO330415 B1 NO 330415B1 NO 20053588 A NO20053588 A NO 20053588A NO 20053588 A NO20053588 A NO 20053588A NO 330415 B1 NO330415 B1 NO 330415B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- phenyl
- methyl
- formula
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 24
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000001544 thienyl group Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- -1 methoxy, ethoxy Chemical group 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 238000005897 peptide coupling reaction Methods 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 230000003959 neuroinflammation Effects 0.000 claims description 3
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000018726 traumatic encephalopathy Diseases 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 17
- 239000004365 Protease Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 108091005804 Peptidases Proteins 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 239000000203 mixture Substances 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012429 reaction media Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 7
- FWVNWTNCNWRCOU-SCSAIBSYSA-N (2s)-2-hydroxy-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](O)C(O)=O FWVNWTNCNWRCOU-SCSAIBSYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical compound S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZOFRUWPIASCICK-UHFFFAOYSA-N 2-(2,5-dimethylthiophen-3-yl)acetic acid Chemical compound CC1=CC(CC(O)=O)=C(C)S1 ZOFRUWPIASCICK-UHFFFAOYSA-N 0.000 description 3
- PGLXPQAKVJMSMN-UHFFFAOYSA-N 2-(5-methylthiophen-2-yl)acetic acid Chemical compound CC1=CC=C(CC(O)=O)S1 PGLXPQAKVJMSMN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RKXSWLZIRWARDF-RBBKRZOGSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-oxo-1-[[5-[2-(pyridin-4-yloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=NC=C1 RKXSWLZIRWARDF-RBBKRZOGSA-N 0.000 description 2
- ZOJJSXIGXAZFDQ-ZCYQVOJMSA-N (2s)-3-ethyl-2-hydroxy-n-[(2s)-1-oxo-1-[[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(CC)CC)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 ZOJJSXIGXAZFDQ-ZCYQVOJMSA-N 0.000 description 2
- PCPMMMUXDLCTCY-XUZZJYLKSA-N (2s)-n-[(2s)-1-[[5-[2-[(2-cyanophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1C#N PCPMMMUXDLCTCY-XUZZJYLKSA-N 0.000 description 2
- YHFAVYIIUQUXDB-LADGPHEKSA-N (2s)-n-[(2s)-1-[[5-[2-[(3-cyanophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(C#N)=C1 YHFAVYIIUQUXDB-LADGPHEKSA-N 0.000 description 2
- MBJNVIFBWMTUSE-UHFFFAOYSA-N 3-ethyl-2-hydroxypentanoic acid Chemical compound CCC(CC)C(O)C(O)=O MBJNVIFBWMTUSE-UHFFFAOYSA-N 0.000 description 2
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 2
- YUSDDNTYMDWOCY-UHFFFAOYSA-N 3-thiophen-3-ylpropanoic acid Chemical compound OC(=O)CCC=1C=CSC=1 YUSDDNTYMDWOCY-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- GADHDPREXDXVCI-UHFFFAOYSA-N 5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 GADHDPREXDXVCI-UHFFFAOYSA-N 0.000 description 2
- SPFKHSYTGILITD-UHFFFAOYSA-N 5-[2-(pyridin-4-yloxymethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC=C1C1=CC=CC=C1COC1=CC=NC=C1 SPFKHSYTGILITD-UHFFFAOYSA-N 0.000 description 2
- DWUPYMSVAPQXMS-UHFFFAOYSA-N 5-bromo-1,3-thiazole Chemical compound BrC1=CN=CS1 DWUPYMSVAPQXMS-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000015499 Presenilins Human genes 0.000 description 2
- 108010050254 Presenilins Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- ZOJJSXIGXAZFDQ-UKILVPOCSA-N (2r)-3-ethyl-2-hydroxy-n-[(2s)-1-oxo-1-[[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@H](O)C(CC)CC)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 ZOJJSXIGXAZFDQ-UKILVPOCSA-N 0.000 description 1
- FJVSSPAHRHFJEX-PMCHYTPCSA-N (2s)-2-[(2-hydroxy-3-phenylpropanoyl)amino]-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC=1C=CC=CC=1)C(=O)C(O)CC1=CC=CC=C1 FJVSSPAHRHFJEX-PMCHYTPCSA-N 0.000 description 1
- MMGKTMUYECNOPU-SANMLTNESA-N (2s)-2-[3-(2,4-dichlorophenyl)propanoylamino]-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC=1C=CC=CC=1)C(=O)CCC1=CC=C(Cl)C=C1Cl MMGKTMUYECNOPU-SANMLTNESA-N 0.000 description 1
- YBMWOVLYBKWMMJ-GMAHTHKFSA-N (2s)-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 YBMWOVLYBKWMMJ-GMAHTHKFSA-N 0.000 description 1
- ZIVWIBFOSHADLH-UPVQGACJSA-N (2s)-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]-n-[5-[4-methoxy-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC=C(OC)C=C1COC1=CC=CC=C1 ZIVWIBFOSHADLH-UPVQGACJSA-N 0.000 description 1
- PJGVEVAVFVUMLK-UPVQGACJSA-N (2s)-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]-n-[5-[5-methyl-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC(C)=CC=C1COC1=CC=CC=C1 PJGVEVAVFVUMLK-UPVQGACJSA-N 0.000 description 1
- NKVCTNPGPVKFAE-DEOSSOPVSA-N (2s)-2-[[2-(5-methylthiophen-2-yl)acetyl]amino]-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC=1C=CC=CC=1)C(=O)CC1=CC=C(C)S1 NKVCTNPGPVKFAE-DEOSSOPVSA-N 0.000 description 1
- MGNKBNCECVFNKT-FERBBOLQSA-N (2s)-2-amino-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]pentanamide;hydrochloride Chemical compound Cl.S1C(NC(=O)[C@@H](N)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 MGNKBNCECVFNKT-FERBBOLQSA-N 0.000 description 1
- CEKUHYJIFZGOKT-FYYLOGMGSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2r)-1-oxo-1-[[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 CEKUHYJIFZGOKT-FYYLOGMGSA-N 0.000 description 1
- UPJCLDQTBYMKDK-LMSSTIIKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[4-(4-methylpentyl)-5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC(CCCC(C)C)=C1C1=CC=CC=C1COC1=CC=CC=C1 UPJCLDQTBYMKDK-LMSSTIIKSA-N 0.000 description 1
- FZLKHJUUAKHBKY-LADGPHEKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[4-methyl-5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC(C)=C1C1=CC=CC=C1COC1=CC=CC=C1 FZLKHJUUAKHBKY-LADGPHEKSA-N 0.000 description 1
- CPZYEFYAKSYCBH-XUZZJYLKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[5-[2-[(2-methylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1C CPZYEFYAKSYCBH-XUZZJYLKSA-N 0.000 description 1
- OJLJGWSPKCDALH-LADGPHEKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[5-[2-[(3-methylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(C)=C1 OJLJGWSPKCDALH-LADGPHEKSA-N 0.000 description 1
- ZLBHDXAKLQSOFD-LADGPHEKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[5-[4-methyl-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=C(C)C=C1COC1=CC=CC=C1 ZLBHDXAKLQSOFD-LADGPHEKSA-N 0.000 description 1
- XUENTXNBGSXDRM-LADGPHEKSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-[[5-[5-methyl-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC(C)=CC=C1COC1=CC=CC=C1 XUENTXNBGSXDRM-LADGPHEKSA-N 0.000 description 1
- DSKWFGHIMHHWJI-HRAATJIYSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-oxo-1-[[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]propan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)C)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 DSKWFGHIMHHWJI-HRAATJIYSA-N 0.000 description 1
- BUGZKSJANWAIRY-AZUAARDMSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-oxo-1-[[5-[2-(propan-2-yloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC(C)C BUGZKSJANWAIRY-AZUAARDMSA-N 0.000 description 1
- WEEJHDBPNKRTBP-WMZHIEFXSA-N (2s)-2-hydroxy-3,3-dimethyl-n-[(2s)-1-oxo-1-[[5-[2-[[2-(trifluoromethoxy)phenoxy]methyl]phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]butanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1OC(F)(F)F WEEJHDBPNKRTBP-WMZHIEFXSA-N 0.000 description 1
- HKGQZUZRYOXLEQ-PZJWPPBQSA-N (2s)-2-hydroxy-n-[(2s)-1-[[5-[4-methoxy-2-(propan-2-yloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=C(OC)C=C1COC(C)C HKGQZUZRYOXLEQ-PZJWPPBQSA-N 0.000 description 1
- FIVATPKVPPKHKI-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[2-(cyclohexyloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1CCCCC1 FIVATPKVPPKHKI-JTHBVZDNSA-N 0.000 description 1
- DCGSCEYXFRRDNK-GOTSBHOMSA-N (2s)-n-[(2s)-1-[[5-[2-(cyclohexyloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-4-methylpentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)CC(C)C)CCC)=NC=C1C1=CC=CC=C1COC1CCCCC1 DCGSCEYXFRRDNK-GOTSBHOMSA-N 0.000 description 1
- XZACBZBKVSGRCG-HRAATJIYSA-N (2s)-n-[(2s)-1-[[5-[2-(cyclohexyloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopropan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)C)=NC=C1C1=CC=CC=C1COC1CCCCC1 XZACBZBKVSGRCG-HRAATJIYSA-N 0.000 description 1
- BNFJJNYRCYNPPY-PKOBYXMFSA-N (2s)-n-[(2s)-1-[[5-[2-(ethoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COCC BNFJJNYRCYNPPY-PKOBYXMFSA-N 0.000 description 1
- YZUSBAPMAHVXJO-WMZHIEFXSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,3-dichlorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(Cl)=C1Cl YZUSBAPMAHVXJO-WMZHIEFXSA-N 0.000 description 1
- PCAKBEPXOGNEQI-WMZHIEFXSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,3-difluorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(F)=C1F PCAKBEPXOGNEQI-WMZHIEFXSA-N 0.000 description 1
- JGYFFYLYCKKSIH-NBGIEHNGSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,3-dimethoxyphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(OC)=C1OC JGYFFYLYCKKSIH-NBGIEHNGSA-N 0.000 description 1
- CPHMVBCNWQNYFR-WIOPSUGQSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,4-dimethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=C(C)C=C1C CPHMVBCNWQNYFR-WIOPSUGQSA-N 0.000 description 1
- WFVWDXUHMJDHOZ-WIOPSUGQSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,5-dimethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC(C)=CC=C1C WFVWDXUHMJDHOZ-WIOPSUGQSA-N 0.000 description 1
- RGGFVUTVVLTZHJ-NZQKXSOJSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,6-difluorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=C(F)C=CC=C1F RGGFVUTVVLTZHJ-NZQKXSOJSA-N 0.000 description 1
- KGPYOXVHDCLAJG-WIOPSUGQSA-N (2s)-n-[(2s)-1-[[5-[2-[(2,6-dimethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=C(C)C=CC=C1C KGPYOXVHDCLAJG-WIOPSUGQSA-N 0.000 description 1
- BSRPGWTXWMGLKN-WIOPSUGQSA-N (2s)-n-[(2s)-1-[[5-[2-[(2-chloro-4,5-dimethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC(C)=C(C)C=C1Cl BSRPGWTXWMGLKN-WIOPSUGQSA-N 0.000 description 1
- GZEKZOFSVNNIBW-XUZZJYLKSA-N (2s)-n-[(2s)-1-[[5-[2-[(2-chloro-5-methylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC(C)=CC=C1Cl GZEKZOFSVNNIBW-XUZZJYLKSA-N 0.000 description 1
- HXVYEBPJASDXLH-WIOPSUGQSA-N (2s)-n-[(2s)-1-[[5-[2-[(2-ethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1CC HXVYEBPJASDXLH-WIOPSUGQSA-N 0.000 description 1
- VZLKLZDMXLNVDX-NZQKXSOJSA-N (2s)-n-[(2s)-1-[[5-[2-[(2-fluorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1F VZLKLZDMXLNVDX-NZQKXSOJSA-N 0.000 description 1
- FOHLOMOEZIFRKY-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[2-[(3,4-dichlorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=C(Cl)C(Cl)=C1 FOHLOMOEZIFRKY-JTHBVZDNSA-N 0.000 description 1
- VUSBFMJHYKUESR-SQJMNOBHSA-N (2s)-n-[(2s)-1-[[5-[2-[(3,4-dimethoxyphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=C(OC)C(OC)=C1 VUSBFMJHYKUESR-SQJMNOBHSA-N 0.000 description 1
- VOZTZTCADFIDCW-UKILVPOCSA-N (2s)-n-[(2s)-1-[[5-[2-[(3,4-dimethylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=C(C)C(C)=C1 VOZTZTCADFIDCW-UKILVPOCSA-N 0.000 description 1
- MZAKDZXYUZTDPH-UKILVPOCSA-N (2s)-n-[(2s)-1-[[5-[2-[(3,5-dimethoxyphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC(OC)=CC(OC)=C1 MZAKDZXYUZTDPH-UKILVPOCSA-N 0.000 description 1
- DJJKVPXRISBJSU-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[2-[(3-chlorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(Cl)=C1 DJJKVPXRISBJSU-JTHBVZDNSA-N 0.000 description 1
- MIBHJAWZSZVDIF-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[2-[(3-fluorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(F)=C1 MIBHJAWZSZVDIF-JTHBVZDNSA-N 0.000 description 1
- ZUZOQHSZPWFXBP-LADGPHEKSA-N (2s)-n-[(2s)-1-[[5-[2-[(4-chloro-3-methylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=C(Cl)C(C)=C1 ZUZOQHSZPWFXBP-LADGPHEKSA-N 0.000 description 1
- NSQHFBUVQJLDQO-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[4-chloro-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=C(Cl)C=C1COC1=CC=CC=C1 NSQHFBUVQJLDQO-JTHBVZDNSA-N 0.000 description 1
- KOYBSNJFPFZVLC-UKILVPOCSA-N (2s)-n-[(2s)-1-[[5-[4-ethoxy-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=C(OCC)C=C1COC1=CC=CC=C1 KOYBSNJFPFZVLC-UKILVPOCSA-N 0.000 description 1
- IQSJLRQCHDXJRJ-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[4-fluoro-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC=C(F)C=C1COC1=CC=CC=C1 IQSJLRQCHDXJRJ-JTHBVZDNSA-N 0.000 description 1
- UTECFPRBEZZNGX-JTHBVZDNSA-N (2s)-n-[(2s)-1-[[5-[5-fluoro-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)(C)C)CCC)=NC=C1C1=CC(F)=CC=C1COC1=CC=CC=C1 UTECFPRBEZZNGX-JTHBVZDNSA-N 0.000 description 1
- HWPWICZYDDVDQT-DEOSSOPVSA-N (2s)-n-[5-[2-(cyclohexyloxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[(2-pyridin-3-ylacetyl)amino]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC1CCCCC1)C(=O)CC1=CC=CN=C1 HWPWICZYDDVDQT-DEOSSOPVSA-N 0.000 description 1
- KGGZGYGWIFGXSK-QFIPXVFZSA-N (2s)-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[(2-thiophen-2-ylacetyl)amino]butanamide Chemical compound N([C@@H](CC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC=1C=CC=CC=1)C(=O)CC1=CC=CS1 KGGZGYGWIFGXSK-QFIPXVFZSA-N 0.000 description 1
- KQSUYSROCZFCSP-QHCPKHFHSA-N (2s)-n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[(2-thiophen-3-ylacetyl)amino]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC=1C=CC=CC=1)C(=O)CC=1C=CSC=1 KQSUYSROCZFCSP-QHCPKHFHSA-N 0.000 description 1
- OYUQMLWQGCIYIF-NRFANRHFSA-N (2s)-n-[5-[2-(propan-2-yloxymethyl)phenyl]-1,3-thiazol-2-yl]-2-(3-thiophen-3-ylpropanoylamino)pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC(C)C)C(=O)CCC=1C=CSC=1 OYUQMLWQGCIYIF-NRFANRHFSA-N 0.000 description 1
- NOBITHKMSDUHGT-FQEVSTJZSA-N (2s)-n-[5-[2-(propan-2-yloxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[(2-thiophen-2-ylacetyl)amino]pentanamide Chemical compound N([C@@H](CCC)C(=O)NC=1SC(=CN=1)C=1C(=CC=CC=1)COC(C)C)C(=O)CC1=CC=CS1 NOBITHKMSDUHGT-FQEVSTJZSA-N 0.000 description 1
- SXGCHWDANLXGDR-GMAHTHKFSA-N (2s)-n-[5-[2-[(3-fluorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC(F)=C1 SXGCHWDANLXGDR-GMAHTHKFSA-N 0.000 description 1
- RARNOVVJKWNUOC-ZCYQVOJMSA-N (2s)-n-[5-[4-ethoxy-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC=C(OCC)C=C1COC1=CC=CC=C1 RARNOVVJKWNUOC-ZCYQVOJMSA-N 0.000 description 1
- ZZWXYUVAISYATO-GMAHTHKFSA-N (2s)-n-[5-[5-fluoro-2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]-2-[[(2s)-2-hydroxy-3-methylbutanoyl]amino]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CCC)=NC=C1C1=CC(F)=CC=C1COC1=CC=CC=C1 ZZWXYUVAISYATO-GMAHTHKFSA-N 0.000 description 1
- NUSVDASTCPBUIP-UHFFFAOYSA-N (5-bromo-1,3-thiazol-2-yl)azanium;bromide Chemical compound [Br-].BrC1=C[NH2+]C(=N)S1 NUSVDASTCPBUIP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- LZSYGJNFCREHMD-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1Br LZSYGJNFCREHMD-UHFFFAOYSA-N 0.000 description 1
- MUVRARONQUQSLM-UHFFFAOYSA-N 1-bromo-2-(phenoxymethyl)benzene Chemical compound BrC1=CC=CC=C1COC1=CC=CC=C1 MUVRARONQUQSLM-UHFFFAOYSA-N 0.000 description 1
- NOZKFTCKOREAKE-UHFFFAOYSA-N 2-(2,5-dimethylthiophen-3-yl)-1-morpholin-4-ylethanethione Chemical compound S1C(C)=CC(CC(=S)N2CCOCC2)=C1C NOZKFTCKOREAKE-UHFFFAOYSA-N 0.000 description 1
- DGFKICCPAPHZJC-UHFFFAOYSA-N 2-(5-methylthiophen-2-yl)-1-morpholin-4-ylethanethione Chemical compound S1C(C)=CC=C1CC(=S)N1CCOCC1 DGFKICCPAPHZJC-UHFFFAOYSA-N 0.000 description 1
- UNNGUFMVYQJGTD-UHFFFAOYSA-N 2-Ethylbutanal Chemical compound CCC(CC)C=O UNNGUFMVYQJGTD-UHFFFAOYSA-N 0.000 description 1
- IZPLKGRLOYRUSF-QHELBMECSA-N 2-hydroxy-n-[(2s)-1-[[5-[2-[(2-methoxyphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)C(O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1OC IZPLKGRLOYRUSF-QHELBMECSA-N 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- PUSJAEJRDNPYKM-UHFFFAOYSA-N 3-Acetyl-2,5-dimethylthiophene Chemical compound CC(=O)C=1C=C(C)SC=1C PUSJAEJRDNPYKM-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- BTFRJEJWOVZRQU-CVMIBEPCSA-N 3-methyl-2-oxo-n-[(2s)-1-oxo-1-[[5-[2-(propan-2-yloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]pentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)C(=O)C(C)CC)CCC)=NC=C1C1=CC=CC=C1COC(C)C BTFRJEJWOVZRQU-CVMIBEPCSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- ARHCLXWELPFVFQ-UHFFFAOYSA-N 5-bromo-1,3-thiazol-2-amine Chemical compound NC1=NC=C(Br)S1 ARHCLXWELPFVFQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- UTIXZTQEIIIFEO-UHFFFAOYSA-N [2-(2-amino-1,3-thiazol-5-yl)phenyl]methanol Chemical compound S1C(N)=NC=C1C1=CC=CC=C1CO UTIXZTQEIIIFEO-UHFFFAOYSA-N 0.000 description 1
- BROFDLKZYPPYGJ-UHFFFAOYSA-N [2-(phenoxymethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1COC1=CC=CC=C1 BROFDLKZYPPYGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- JVKOMXUTXGBJFC-ONEGZZNKSA-N ethyl (e)-3-thiophen-3-ylprop-2-enoate Chemical compound CCOC(=O)\C=C\C=1C=CSC=1 JVKOMXUTXGBJFC-ONEGZZNKSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- PFZJNAYIFUAPPE-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-1,1-diphenylmethanimine Chemical compound S1C(Br)=CN=C1N=C(C=1C=CC=CC=1)C1=CC=CC=C1 PFZJNAYIFUAPPE-UHFFFAOYSA-N 0.000 description 1
- DCGSCEYXFRRDNK-NQCNTLBGSA-N n-[(2s)-1-[[5-[2-(cyclohexyloxymethyl)phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-4-methylpentanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)C(O)CC(C)C)CCC)=NC=C1C1=CC=CC=C1COC1CCCCC1 DCGSCEYXFRRDNK-NQCNTLBGSA-N 0.000 description 1
- LSNRQEHAXZSIAV-AJZOCDQUSA-N n-[(2s)-1-[[5-[2-[(2,6-dichlorophenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)C(O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=C(Cl)C=CC=C1Cl LSNRQEHAXZSIAV-AJZOCDQUSA-N 0.000 description 1
- CYIGLAULRQNNSW-BWDMCYIDSA-N n-[(2s)-1-[[5-[2-[(2-ethoxyphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]amino]-1-oxopentan-2-yl]-2-hydroxy-3,3-dimethylbutanamide Chemical compound S1C(NC(=O)[C@@H](NC(=O)C(O)C(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1OCC CYIGLAULRQNNSW-BWDMCYIDSA-N 0.000 description 1
- QQQDNVZDCMTNHM-UHFFFAOYSA-N n-[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]-1,1-diphenylmethanimine Chemical compound C=1C=CC=C(C=2SC(N=C(C=3C=CC=CC=3)C=3C=CC=CC=3)=NC=2)C=1COC1=CC=CC=C1 QQQDNVZDCMTNHM-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JOFYSNKXAMDQAH-NRFANRHFSA-N tert-butyl n-[(2s)-1-oxo-1-[[5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl]amino]pentan-2-yl]carbamate Chemical compound S1C(NC(=O)[C@@H](NC(=O)OC(C)(C)C)CCC)=NC=C1C1=CC=CC=C1COC1=CC=CC=C1 JOFYSNKXAMDQAH-NRFANRHFSA-N 0.000 description 1
- XOAROBSFZGTVKO-UHFFFAOYSA-N tert-butyl n-[5-[2-(hydroxymethyl)phenyl]-1,3-thiazol-2-yl]carbamate Chemical compound S1C(NC(=O)OC(C)(C)C)=NC=C1C1=CC=CC=C1CO XOAROBSFZGTVKO-UHFFFAOYSA-N 0.000 description 1
- MCOAXFQZEUTWQZ-UHFFFAOYSA-N tert-butyl n-[5-[2-(pyridin-4-yloxymethyl)phenyl]-1,3-thiazol-2-yl]carbamate Chemical compound S1C(NC(=O)OC(C)(C)C)=NC=C1C1=CC=CC=C1COC1=CC=NC=C1 MCOAXFQZEUTWQZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- IERBVBGUKBHALB-UHFFFAOYSA-K tripotassium;phosphate;dihydrate Chemical compound O.O.[K+].[K+].[K+].[O-]P([O-])([O-])=O IERBVBGUKBHALB-UHFFFAOYSA-K 0.000 description 1
- KPZYAGQLBFUTMA-UHFFFAOYSA-K tripotassium;phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].[K+].[O-]P([O-])([O-])=O KPZYAGQLBFUTMA-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0300703A FR2850380B1 (fr) | 2003-01-23 | 2003-01-23 | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
| PCT/FR2004/000140 WO2004067520A1 (fr) | 2003-01-23 | 2004-01-22 | Derives d'acylaminothiazole, leur preparation et leur utilisation en tant qu’inhibiteurs de la production du peptide beta-amyloide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20053588D0 NO20053588D0 (no) | 2005-07-22 |
| NO20053588L NO20053588L (no) | 2005-09-22 |
| NO330415B1 true NO330415B1 (no) | 2011-04-11 |
Family
ID=32669150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053588A NO330415B1 (no) | 2003-01-23 | 2005-07-22 | Acylaminotiazol-derivater, fremgangsmate for fremstilling derav, anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer og farmasoytisk sammemsetning inneholdende de samme |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7563903B2 (zh) |
| EP (1) | EP1590337B1 (zh) |
| JP (1) | JP2006515888A (zh) |
| KR (1) | KR101059669B1 (zh) |
| CN (1) | CN100532370C (zh) |
| AR (1) | AR042745A1 (zh) |
| AT (1) | ATE404545T1 (zh) |
| AU (1) | AU2004207658B2 (zh) |
| BR (1) | BRPI0406893A (zh) |
| CA (1) | CA2511610A1 (zh) |
| DE (1) | DE602004015726D1 (zh) |
| FR (1) | FR2850380B1 (zh) |
| HR (1) | HRP20050637A2 (zh) |
| IL (1) | IL169428A (zh) |
| MA (1) | MA27610A1 (zh) |
| ME (1) | MEP16708A (zh) |
| MX (1) | MXPA05007847A (zh) |
| NO (1) | NO330415B1 (zh) |
| NZ (1) | NZ541147A (zh) |
| PL (1) | PL377999A1 (zh) |
| RS (1) | RS51168B (zh) |
| RU (1) | RU2360907C2 (zh) |
| TW (1) | TWI320710B (zh) |
| WO (1) | WO2004067520A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009344A2 (en) * | 2003-06-05 | 2005-02-03 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| AU2007207743B2 (en) * | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| WO2009108760A2 (en) | 2008-02-26 | 2009-09-03 | Board Of Regents, The University Of Texas System | Dendritic macroporous hydrogels prepared by crystal templating |
| EP2371421A1 (en) * | 2010-03-04 | 2011-10-05 | Université de Lille 2 Droit et Santé | Ligands of insulin degrading enzyme and their uses |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| CN103145692B (zh) * | 2013-03-12 | 2014-07-16 | 盐城工学院 | 一种4,5-二氢-6H-环戊烷并[b]噻吩-6-酮的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000069075A (ko) * | 1996-11-22 | 2000-11-25 | 진 엠. 듀발 | Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법 |
| ES2319239T3 (es) * | 1996-12-23 | 2009-05-05 | Elan Pharmaceuticals, Inc. | Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos y procedimientos para inhibir la liberacion del peptido beta-amiloide y/o sintesis mediante el uso de tales compuestos. |
| ES2237919T4 (es) * | 1998-06-18 | 2007-05-01 | Bristol-Myers Squibb Company | Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina. |
| AU6229699A (en) * | 1998-10-26 | 2000-05-15 | Sumitomo Pharmaceuticals Company, Limited | Beta-amyloid formation inhibitors |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
-
2003
- 2003-01-23 FR FR0300703A patent/FR2850380B1/fr not_active Expired - Fee Related
-
2004
- 2004-01-22 CA CA002511610A patent/CA2511610A1/en not_active Abandoned
- 2004-01-22 RS YUP-2005/0563A patent/RS51168B/sr unknown
- 2004-01-22 NZ NZ541147A patent/NZ541147A/en not_active IP Right Cessation
- 2004-01-22 WO PCT/FR2004/000140 patent/WO2004067520A1/fr active IP Right Grant
- 2004-01-22 PL PL377999A patent/PL377999A1/pl not_active Application Discontinuation
- 2004-01-22 MX MXPA05007847A patent/MXPA05007847A/es active IP Right Grant
- 2004-01-22 JP JP2006502115A patent/JP2006515888A/ja not_active Ceased
- 2004-01-22 AR ARP040100169A patent/AR042745A1/es unknown
- 2004-01-22 DE DE602004015726T patent/DE602004015726D1/de not_active Expired - Lifetime
- 2004-01-22 CN CNB2004800027812A patent/CN100532370C/zh not_active Expired - Fee Related
- 2004-01-22 AT AT04704255T patent/ATE404545T1/de not_active IP Right Cessation
- 2004-01-22 RU RU2005126608/04A patent/RU2360907C2/ru not_active IP Right Cessation
- 2004-01-22 AU AU2004207658A patent/AU2004207658B2/en not_active Ceased
- 2004-01-22 KR KR1020057013441A patent/KR101059669B1/ko not_active IP Right Cessation
- 2004-01-22 ME MEP-167/08A patent/MEP16708A/xx unknown
- 2004-01-22 EP EP04704255A patent/EP1590337B1/fr not_active Expired - Lifetime
- 2004-01-22 BR BR0406893-9A patent/BRPI0406893A/pt not_active IP Right Cessation
- 2004-01-27 TW TW093101748A patent/TWI320710B/zh not_active IP Right Cessation
-
2005
- 2005-06-27 IL IL169428A patent/IL169428A/en not_active IP Right Cessation
- 2005-07-12 HR HR20050637A patent/HRP20050637A2/hr not_active Application Discontinuation
- 2005-07-12 MA MA28385A patent/MA27610A1/fr unknown
- 2005-07-21 US US11/186,507 patent/US7563903B2/en not_active Expired - Fee Related
- 2005-07-22 NO NO20053588A patent/NO330415B1/no not_active IP Right Cessation
-
2009
- 2009-06-22 US US12/488,658 patent/US7879889B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002254099B2 (en) | Cathepsin cysteine protease inhibitors | |
| US7879889B2 (en) | Therapeutic use of acylaminothiazole derivatives | |
| US7795289B2 (en) | Use of acylaminothiazole derivatives as therapeutic agents | |
| CA2636826C (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| US20080058380A1 (en) | Acylaminothiazole derivatives, their preparation and their therapeutic use | |
| US7759377B2 (en) | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | |
| AU2002254099A1 (en) | Cathepsin cysteine protease inhibitors | |
| AU2005209442B2 (en) | Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics | |
| ES2369918T3 (es) | Derivados de acilaminotiazol y su aplicación como inhibidores de beta-amiloide. | |
| MXPA06008040A (es) | Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |